SPECT Imaging for Pharmacokinetics and dosimEtry Towards TREATment Optimization

Not yet recruiting

• Conditions: Prostate Cancer; Advanced Cancer

• Registration Number: NCT06389097
• Lead Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2024-4-24
• Last Update Posted: 2 September 2024

Recruitment & Eligibility

• Status: Not yet recruiting
• Sex: All
• Target Recruitment: 80

Inclusion Criteria

Inclusion Criteria:<br><br> - Cohort A: Patients with advanced prostate cancer planning to undergo treatment with<br> Radium-223<br><br> - Cohort B: Patients with advanced cancer undergoing treatment with 177Lu-DOTATATE or<br> 177Lu-PSMA-617<br><br> **Eligible patients may be planning to undergo these treatments as part of standard<br> of care or as part of another research protocol<br><br> - Age > 18 years<br><br> - Eastern Cooperative Oncology Group (ECOG) performance status = 2<br><br> - Histologic confirmation of malignancy<br><br>Exclusion Criteria:<br><br> - Patient is participating in another research protocol that does not allow<br> participation in this imaging protocol or that has schedule of procedures that would<br> not be compatible with this protocol.<br><br> - Patient unable to tolerate SPECT scan time, scan frequency, or position.

Exclusion Criteria

Not provided

Study & Design

• Study Type: Observational
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Mean absorbed dose to normal organs compared using different quantitative methods

Secondary Outcome Measures

Name	Time	Method
Variability of intra-patient and inter-patient mean absorbed dose to normal organs compared using SPECT images;Mean absorbed dose to normal organs correlated with toxicity